TH9 immunodeficiency in patients with hyper-IgE syndrome

Slides:

Advertisements

Similar presentations

Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.

Advertisements

Characteristics of childhood peanut allergy in the Australian Capital Territory, 1995 to 2007 Raymond James Mullins, MBBS, PhD, FRACP, FRCPA, Keith B.G.

D-dimer: A biomarker for antihistamine-resistant chronic urticaria

Peter Vadas, MD, PhD, Boris Perelman, PhD, Gary Liss, MD, MS

Challenges of genetic counseling in patients with autosomal dominant diseases, such as the hyper-IgE syndrome (STAT3-HIES) Benedikt D. Spielberger, Cristina.

Fatty acids, inflammation, and asthma

Defects of class-switch recombination

Laurent L'homme, PhD, David Dombrowicz, PhD

Advances in food allergy in 2015

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD

Complete remission in 3 of 3 anti-IL-6–treated patients with Schnitzler syndrome Karoline Krause, MD, Eugen Feist, MD, Michael Fiene, MD, Tilmann Kallinich,

David A. Khan, MD Journal of Allergy and Clinical Immunology

Is 9 more than 2 also in allergic airway inflammation?

Desensitization to Chemotherapeutic Agents

Fatty acids, inflammation, and asthma

Rising prevalence of asthma is sex-specific in a US farming population

Lieuwe D. Bos, MSc, PhD, Peter J. Sterk, MD, PhD, Stephen J

Allergy testing in predicting outcome of open food challenge to peanut

Bruton tyrosine kinase inhibition: Clinical relevance beyond B cells

Nonadherence to Asthma Treatment: Getting Unstuck

Etiology of asthma exacerbations

Practice Notes from the AAAAI

Jewlya Lynn, PhD, Sophie Oppenheimer, MS, MPH, Lorena Zimmer, MA

Biologics and biomarkers for asthma, urticaria, and nasal polyposis

Possible role of TH17 cells in the pathogenesis of Stevens-Johnson syndrome and toxic epidermal necrolysis Yuichi Teraki, MD, Misaki Kawabe, MD, Seiichi.

A survivor: The eosinophil as a regulator in asthma

Immunopathophysiology of food protein–induced enterocolitis syndrome

Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation Leif Bjermer, MD Journal of Allergy.

Food allergy in patients with primary immunodeficiency diseases: Prevalence within the US Immunodeficiency Network (USIDNET) Karen S. Tuano, MD, Jordan.

News & Notes Journal of Allergy and Clinical Immunology

Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management Scott H. Sicherer, MD, Hugh A. Sampson, MD Journal.

Biosimilars and drug development in allergic and immunologic diseases

Christian Hennig, MD, Christine Happle, MD, Gesine Hansen, MD

News Beyond Our Pages Journal of Allergy and Clinical Immunology

Invasive fungal disease in autosomal-dominant hyper-IgE syndrome

Peter Vadas, MD, PhD, Boris Perelman, PhD, Gary Liss, MD, MS

What is an “eosinophilic phenotype” of asthma?

Weiguo Chen, PhD, Gurjit K. Khurana Hershey, MD, PhD

Liam O’Mahony, PhD, Mübeccel Akdis, MD, PhD, Cezmi A. Akdis, MD

H. William Kelly, PharmD Journal of Allergy and Clinical Immunology

Cockroach allergens: Coping with challenging complexity

Autophagy: Nobel Prize 2016 and allergy and asthma research

IL-2– and CD25-dependent immunoregulatory mechanisms in the homeostasis of T-cell subsets Sven Létourneau, DPhil, Carsten Krieg, PhD, Giuseppe Pantaleo,

News & Notes Journal of Allergy and Clinical Immunology

Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment

Advances in the approach to the patient with food allergy

Geographic variability in childhood asthma prevalence in Chicago

New pathways for itching in patients with atopic dermatitis?

Bruce G. Bender, PhD, Alex Pedan, PhD, Laleh T. Varasteh, RPh, MSF

One step forward, 2 steps back: The enigma of preschool wheeze

Benjamin Chaigne, MD, Hervé Watier, MD, PhD

Practice Notes from the AAAI

Measles and immunomodulation

Asthma progression: Can we and should we measure it?

Macrolide antibiotics and asthma treatment

Immune pathomechanism of drug hypersensitivity reactions

Statistical issues in clinical trials that involve the double-blind, placebo-controlled food challenge Vernon M. Chinchilli, PhD, Laura Fisher, MD, Timothy.

Asthma: The past, future, environment, and costs

Interrupting IL-6–receptor signaling improves atopic dermatitis but associates with bacterial superinfection Alexander A. Navarini, MD, PhD, Lars E.

Janet Chou, MD, Maxim Lutskiy, MD, PhD, Erdyni Tsitsikov, PhD, Luigi D

Asthma Control Test: Reliability, validity, and responsiveness in patients not previously followed by asthma specialists Michael Schatz, MD, MS, Christine.

Environmental factors and eosinophilic esophagitis

Kinase inhibitors in clinical practice: An expanding world

News & Notes Journal of Allergy and Clinical Immunology

Systemic responses after bronchial aspirin challenge in sensitive patients with asthma Joanna S. Makowska, MD, PhD, Janina Grzegorczyk, PhD, Barbara Bienkiewicz,

The use of serum-specific IgE measurements for the diagnosis of peanut, tree nut, and seed allergy Jennifer M. Maloney, MD, Magnus Rudengren, BSc, Staffan.

Advances in pediatric asthma in 2007

Natural history of cow’s milk allergy

Primary prevention of asthma and allergy

Itching as a systemic disease

Presentation transcript:

TH9 immunodeficiency in patients with hyper-IgE syndrome Matthew R. Olson, PhD, Mark H. Kaplan, PhD Journal of Allergy and Clinical Immunology Volume 143, Issue 3, Pages 935-936 (March 2019) DOI: 10.1016/j.jaci.2018.10.044 Copyright © 2018 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 1 Effect of STAT3 in TH9 development. In developing human TH9 cells (left), activation of STAT3 induces SOCS3, which represses the inhibitory STAT1 pathway activation but does not seem to affect the IL-9–promoting effects of STAT5. In patients with HIES with STAT3 LOF mutations, control of the inhibitory pathway is lost. In contrast, in developing mouse TH9 cells (right), STAT3 activation inhibits STAT5 activation that is required for maximal IL-9 production. Mouse STAT3 activation can also interfere with STAT1 activation, although the inhibitory effects of STAT1 in mouse cells is less defined, and the loss of STAT5 activation is the dominant effect. BCL6, B-cell lymphoma 6; SOCS3, suppressor of cytokine signaling 3. Journal of Allergy and Clinical Immunology 2019 143, 935-936DOI: (10.1016/j.jaci.2018.10.044) Copyright © 2018 American Academy of Allergy, Asthma & Immunology Terms and Conditions